{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.9","value":"3.0"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"1038"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"1038"}],"units":"cycles"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.","dispersionType":"Standard Deviation","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"MEAN","populationDescription":"Cycles of patients in evaluable sample with study drug initiation day at cycle 4","reportingStatus":"POSTED","timeFrame":"Cycle 4. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician.","title":"EP2006 Day of Initiation: Cycle 4","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"days"}